Thierry Andre

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Thierry Andre
Jan 28, 2025, 17:20 | Insight
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post…
Jan 28, 2025, 06:19 | Science
Yakup Ergün: The New Standard of Care in MSI-H CRC-Nivolumab + Ipilimumab
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a recent article by Thierry Andre…
Dec 20, 2024, 13:21 | Insight
Agenus has Announced Five Presentations at 2025 ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal…
Dec 4, 2024, 17:52 | Blog
Anirban Maitra: Amazing combo ICI results but an unfair comparator arm
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center,…
Nov 30, 2024, 16:17 | Insight
Vivek Subbiah: The development of immunotherapy in MSI-H and D-MMR cancers by Thierry Andre et al.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Sep 10, 2024, 04:33 | Blog
Elias Karam: ACCENT pooled analysis published in JCO
Elias Karam, Hematology and Medical Oncology Fellow at Gustave Roussy, shared a post on LinkedIn…
Aug 7, 2024, 00:27 | Blog
Paolo Tarantino reflects on the results from DESTINY-CRC02 published in the Lancet Oncology
Paolo Tarantino shared on X: “Results from DESTINY-CRC02 published in the Lancet Oncology. Among patients…
All: 7 Posts: 1 - 100
Special Coverage